Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 3/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17718485 | 0.87 | SMN1; SMN2 (0.56) | CA12CA1CA2CA7CA13 | |
| SCHEMBL17718486 | 0.81 | CA12 (0.55) | CA12CA1CA2CA7CA13 | |
| SCHEMBL20436778 | 0.77 | — | — | |
| SCHEMBL20436768 | 0.77 | — | — | |
| SCHEMBL20436774 | 0.77 | CA12 (0.42) | CA12CA1CA2CA7CA13 | |
| SCHEMBL12180002 | 0.76 | — | — | |
| SCHEMBL13778590 | 0.73 | CA12 (0.54) | CA12CA1CA2CA7CA13 | |
| SCHEMBL87230 | 0.73 | — | — | |
| SCHEMBL18257672 | 0.72 | CA12 (0.41) | CA12CA1CA2CA7CA13 | |
| SCHEMBL12912878 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310625-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-10-05 | — | — | US | disclosed |
| US-20230310625-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-10-05 | — | — | US | disclosed |
| US-11672871-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672871-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20200254109-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-08-13 | — | — | US | disclosed |
| US-10675356-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180214567-A1 | Peptide Oligonucleotide Conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180214567-A1 | Peptide Oligonucleotide Conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214567-A1 | Peptide Oligonucleotide Conjugates | MYOF, MUSK, MTPN | CA12 2063/4885CA1 3676/4885CA2 4261/4885 |
| US-20230310625-A1 | Peptide Oligonucleotide Conjugates | MYOF, MUSK, MTPN | CA12 2063/4885CA1 3676/4885CA2 4261/4885 |
| US-10675356-B2 | Peptide oligonucleotide conjugates | MYOF, MUSK, MTPN | CA12 2063/4885CA1 3676/4885CA2 4261/4885 |
| US-20200254109-A1 | Peptide Oligonucleotide Conjugates | MYOF, MUSK, MTPN | CA12 2063/4885CA1 3676/4885CA2 4261/4885 |
| US-11672871-B2 | Peptide oligonucleotide conjugates | MYOF, MUSK, MTPN | CA12 2063/4885CA1 3676/4885CA2 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.